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Introduction
Many autoimmune conditions are chronic and will require long-term control. Gene therapy provides the potential for long-term delivery and several viral and nonviral vectors have been employed to deliver genes to mammalian cells. Some of the most widely used vectors are based on Moloney murine leukemia virus (MoMLV). 1 Recent progress has been made in addressing some of the questions concerning their use for nondividing targets, the safety of the vector, the transcriptional repression events in the viral genome as well as the longevity of the expressed gene. [1] [2] [3] Cytokines are important immunological mediators, with both pro-and antiinflammatory properties. Delivery of cytokine inhibitors and inhibitory cytokine genes provides a means to control autoimmune disease. [4] [5] [6] [7] Type I interferons (IFN␣ and IFN␤) have been used clinically for the past 10-15 years for the treatment of a variety of viral and oncogenic diseases. 8 Recent studies also show that IFN␤ has a beneficial effect on the disease course in relapsing-remitting multiple sclerosis (MS) patients, shown by reductions in both the magnetic resonance imaging lesions and the severity and frequency of relapse. 9, 10 Unlike clinical trials with IFN␥ which have led to a worsening of the clinical state, the former has shown certain benefit. 9, 11 As IFN␤ fails to exhibit interspecies cross-reactivity, little experimental work has been performed in experimental models and little is known about the mechanism by which this cytokine influences the disease; although, beneficial effects in the Lewis rat experimental allergic encephalomyelitis (EAE) model of MS have been found when protein IFN␤ was administered subcutaneously during the induction phase. 12 Rat recombinant IFN␤ effectively prevents acute EAE in Lewis rats, 13 and furthermore, EAE is also effectively inhibited by type I interferons administered by different routes. 14 There is growing evidence implicating an important role of TNF in the pathogenesis of chronic relapsing experimental allergic encephalomyelitis (CREAE). 15, 16 TNF␣ was detected in lesions within the central nervous system (CNS) suggesting that the CNS may be the main site for TNF-specific immunomodulation. This was further supported by the observation that intracranial injection of TNF antagonists were significantly more potent than when administered systemically, for both anti-TNF antibody and TNF receptor-Ig (TNFR/Ig) chimeric protein. 16 Cytokines have a pleiotropic effect and thus systemic administration of protein may lead to undesirable consequences. Therefore, local delivery into the target tissue may be preferable. The therapeutic effect of anti-TNF treatment in CREAE models, the beneficial effects of anti-TNF antibody in other autoimmune diseases such as human rheumatoid arthritis 17 and Crohn's disease, 18 as well as the beneficial effect of IFN␤ in MS, led to this study to clone and test a TNF␣ antagonist along with the mouse IFN␤ for gene therapy in a CREAE model.
The DNA sequences of the mouse IFN␤ and human bivalent p55 extracellular domain TNF receptor linked to a murine immunoglobulin backbone, 19 were expressed in a retrovirus vector of the pBabe series. 20 These were characterized biochemically following their expression in vitro in various cells as well as in biological assays. In order to obtain tissue-specific expression, the murine IFN␤ gene was cloned and expressed under the control of the neuron specific enolase (NSE) promoter. 21 Treatment of CREAE with IFN␤ or TNFR/Ig delivered locally as a DNA into the CNS via cationic liposomes, effectively inhibited the acute phase of CREAE by reducing the clinical severity of the disease.
Results
Retrovirus vector expressing the murine IFN␤ gene A retrovirus expression vector, named ApHRO, was constructed that expressed murine IFN␤ which was assembled as shown in Figure 1 . The genomic open reading frame was amplified by PCR as a product of 579 bp. The PCR product was first cloned into the SmaI site of pUC18 plasmid and positive clones identified by restric- tion enzyme digestion and by sequencing. One clone, K1, provided the IFN␤ sequence for subcloning into the retrovirus vector pBabeBleo. This vector contains a MoMLV LTR promoter, a phleomycin resistance gene under the control of an SV40 promoter and an ampicillin resistance gene. The murine IFN␤ sequence was inserted into the multiple cloning site of the retrovirus vector, 3′ to the gag gene and 5′ to the SV40 promoter as shown in Figure 1 .
This construct was tested for expression of the inserted gene by transient transfections in COS-7 and in NB100 neuroblastoma cells, and their serum-free supernatants were analyzed by Western blotting (Figure 2 ). The murine IFN␤ gene product was detected in the supernatants of COS-7 transfectants (Figure 2b , lane 1S) as a band of apparent molecular weight of approximately 18 kDa, using a polyclonal rabbit anti-IFN␤ antibody and was not detected intracellularly ( Figure 2b, lane 1C) . A similar band was not present in the COS-7 untransfected cells which were used as controls (Figure 2b , lanes 4C and 4S). Supernatants from NB100 cells produced two forms of IFN␤ (Figure 2a , lanes 1S and 2S), of 18 and 21 kDa, respectively. In both COS-7 and NB100 cell transfectants the LTR-driven IFN␤ gene is constitutively expressed.
Expression of IFN␤ gene under the control of the NSE promoter In order to achieve tissue-specific expression of murine IFN␤, constructs were assembled with or without a polyadenylation signal carrying the rat neuron-specific enolase promoter (NSE), which is tissue specific for neuron cells (clone 6 and NIKI, respectively). Both constructs contained a 1800 bp 5′ flanking sequence upstream of the exon I of the rat NSE gene, plus 50 bp downstream of intron I. 21 The construct was built in a multi-step cloning procedure as depicted in Figure 3 .
Transient transfections of the murine IFN␤ gene with (NIKI) or without (clone 6) a polyadenylation signal were performed in COS-7 fibroblasts and NB100 neuroblastoma cells, and tested by Western blot analysis (Figure 2a and b, lanes 2S and 3S). The murine IFN␤ gene product was detected in the supernatants as two bands with molecular weights of 18 kDa and approximately 21 kDa. These bands were not present in the untransfected COS-7 or NB100 cells (controls, Figure 2a and b, lanes 4S and 4C) or supernatants from the clone 6 transfectants (a and b, lanes 3S and 3C). Importantly, IFN␤ driven from the NSE promoter was only expressed in neuroblastoma cells and not in COS-7 cells, indicative of selective expression conferred by this tissue-specific promoter (compare a and b, lanes 2S in Figure 2 ).
Biological activity of IFN␤ construct
Stable transfectants expressing IFN␤ in the 5′ MoMLV LTR-driven retrovirus (ApHRO construct) were made in GPenvAM12 packaging cells and used for infection of the ABH mouse fibroblast line. Supernatants from established cell lines were tested for antiviral activity against EMC virus. Protection of the LTK(−) cells by inhibition of the cytopathic effect of the EMC virus by the LTRdriven IFN␤ has been demonstrated ( Table 1 ). The infected mouse fibroblasts produced 32 U/ml of IFN␤ in the growth medium. The COS-7, NB100 cells and the amphotropic packaging cell line of human origin, ␣-BOSC23, transiently transfected with ApHRO construct, produced 8, 2 and 32 U/ml of IFN␤, respectively, as shown in Table 1 . Similar secretion levels were not detected in the transiently transfected COS-7 cells for NIKI and clone 6 transfectants, although a high expression level of IFN␤ was observed in NB100 cells, driven by the NSE promoter (16 U/ml of IFN␤).
Retrovirus expressing the TNF receptor linked to an immunoglobulin backbone
In order to explore the high affinity properties of the TNF-antagonist chimeric protein, which is composed of the extracellular domain of the human p55 TNF receptor linked to an immunoglobulin sequence, 19 and study its expression, a retrovirus expression vector was constructed following the cloning strategy shown in Figure 4 . The 2600 bp ClaI-SalI fragment comprised of the huTNFR extracellular domain (huTNFR-ED in Figure 4 ), a thrombin cleavage site (TCS), the murine IgG hinge with the Fc fragment, the human growth hormone 3′ end untranslated region (hGH 3′UTR) up to SalI restriction site on the pCMV4 map, 22 was removed from the pCMV4 vector and subcloned into the polylinker region of the retrovirus vector pBabeBleo resulting in a new construct named Hermes.
Biochemical characterization of p55 TNF-R/Ig chimeric protein Transfectants expressing the huTNFR/Ig were made with Hermes in amphotropic packaging cell lines (GPenvAM12, ␣-BOSC23) or in immortalized mouse fibroblasts. These cells produced the chimeric protein which was detected in the growth media. Transient transfectants were also made in COS-7 fibroblasts and their serum-free supernatants were tested, after concentration, by Western blot analysis. The human p55 TNFR/Ig was detected in the supernatants of Hermes COS-7 transfectants as a band of apparent molecular weight of approximately 150 kDa ( Figure 5 ). This band was not present in the cell fraction in the COS-7 untransfected controls.
Biological activity of p55 TNF-R/Ig
The expressed human p55 TNFR/Ig was tested, for the protective effect against TNF cytotoxic activity, on WEHI 164 TNF-sensitive cells. This protective effect was assessed when human TNF␣ was preincubated with various dilutions of culture medium from permanently or transiently Hermes transfected cells ( Figure 6 , GPenv-
Figure 3 Cloning of rat NSE promoter and murine IFN␤ gene into the plasmid vector pGL2-basic. The different stages of cloning strategy are (a) the construction of intermediate vector clone 6 without polyadenylation signal and (b) cloning of rat NSE promoter and murine IFN␤ gene into the plasmid vector pGL2-basic carrying the SV40 poly(A) signal sequence (NIKI).
AM12, COS-7 and ␣-BOSC23, Figure 6b , c and d, respectively). In addition to the mock transfectants we used as control virus supernatants from an irrelevant gene construct (Figure 6b, GPenvAM12+) . The transfectant supernatants from the retrovirus construct Hermes and TNFR/Ig chimeric protein in pCMV4 vector (positive controls) from transient COS-7 transfectants protected WEHI cells from the killing effect by human TNF (huTNF), but less efficiently (Figure 6c ), compared to the other transfectant supernatants (Figure 6b and d) . These protection levels, 1:4 diluted supernatant of TNFR/Ig, pCMV4 vector 22 from COS-7 cells, protected 60% of WEHI cells from the killing effect (positive control). In the same assay, the secreted TNFR/Ig chimeric protein in the GpenvAM12 cell medium, diluted approximately 1:4 of the original supernatant, was sufficient to protect more than 85% of WEHI cell population from the killing effect by 62.5 pg/ml of huTNF␣ (Figure 6b ). Similar dilution of either COS-7 or ␣-BOSC23 amphotropic packaging cell supernatants were also sufficient to protect WEHI cell population from the killing effect (Figure 6c and d). In contrast, the levels of protection were negligible for all the cells under the same conditions that had not been transfected ( Figure 6 , eg ␣BOSC23-Control, COS-7-Control, GPenvAM12-Control) or transfected with another, packaged retrovirus supernatant (Figure 6b , GPenvAM12+).
In vivo therapeutic effect of CNS-injected DNA-cationic liposome complex Plasmid DNAs complexed with cationic liposomes were injected intracranially prior to the onset of EAE in ABH mice immunized with spinal cord homogenate in Freund's adjuvant, in an attempt to modulate the disease course of EAE. ABH biozzi mice were given a single injection of 100 g of purified plasmid DNA with 10% lipofectin (1 mg/ml) in a total volume of 30 l, intracranially (i.c.) on day 12 after disease induction. Table 2 and Figure 7 show that mice injected with cationic liposome only had no significant inhibitory effect compared with the PBS control group in either disease severity or time of onset, whereas cytokine DNA-cationic liposome complexes expressing IFN␤ (ApHRO) and human p55 TNFR/Ig (Hermes) all reduced the clinical score to a statistically significant level (P Ͻ 0.05). LTR-driven IFN␤ DNA was more efficient than NSE promoter-driven IFN␤ DNA.
Discussion
This study demonstrates that the retroviruses and plasmids used for the in vitro expression of the murine IFN␤ as well as the human p55 TNFR/Ig were constitutively expressed as detected by Western blot analysis and biological activity of COS-7 and NB100 cell supernatants. Moreover, these vectors when delivered i.c. as cationic liposome-DNA complexes to mice in the effector phase of EAE significantly reduced or prevented the clinical signs of disease. In similar studies, we have also used as control plasmids the bacterial ␤-galactosidase, murine TNF or IL-10 gene without any therapeutic benefit. 6 In the biochemical analysis of both proteins it was found that the molecular weights of the human TNFR/Ig and mIFN␤ were, as expected, at 150 kDa and 18 kDa, respectively, as shown by Western blot analysis. Bioactivity of human TNFR/Ig and mIFN␤ was demonstrated in the bioassay of various infected or transfected cell lines.
The different glycosylation pattern of IFN␤, in COS-7 and NB100 cells, may well explain the two bands at 18 kDa and 21 kDa in the latter. IFN␤ has 166 amino acids (approximately 18 kDa) and is the only IFN that can be glycosylated. 23 It is likely that the band of approximately 21 kDa is the glycosylated form of mIFN␤, which is in accordance with previous reports 23 and determined from the mouse IFN␤ mRNA sequence. 24 The EMC antiviral activity data on LTK (−) cells, by the COS-7 and NB100 cells transiently transfected with NIKI, ApHRO or clone 6 showed differences in the protection levels against EMC virus in LTK (−) cells, due to the fact that the NSE promoter is not functional in a nonneuron-like cell type. The ABH mouse fibroblasts and amphotropic human ␣-BOSC23 produced higher levels of biologically active IFN␤ even higher than neuroblastoma NB100 cells (Table 1) .
It is known that type I IFN plays an important role in T cell differentiation towards a Th1 type of immune response, especially during viral infections. 25 Macrophages and other antigen-presenting cells are the main cell types responsible for the early production of type I IFN. The benefit of IFN␤ treatment in the reduction of the relapse rate to MS patients 11 implies that the mechanism of IFN␤ in the progression of the disease is inhibitory. Recently it has been shown that activated T lymphocytes induce TNF production by microglial cells through VLA-4. IFN␤ inhibits in vitro microglial TNF expression, via inhibition of the adhesion molecule VLA-4. 26 It is plausible that inhibition of expression of VLA-4, which is also necessary for cell migration through endothelium, may explain in part the therapeutic effect in EAE. The feasibility of expressing mIFN␤ by gene therapy in animal models of human disease will help to clarify its role in pathogenesis and its mechanism of action in therapeutic interventions both in autoimmune diseases and cancer, since studies with mIFN␤-producing tumor cells are not yet available.
The expression of human-p55 TNFR/Ig (Hermes) showed a highly active TNF inhibitor protecting WEHI 164 cells from cytotoxic TNF. Genetically engineered cells producing human-p55 TNFR/Ig such as those produced here could be used for ex vivo gene therapy studies in inflammation and autoimmune diseases. This cytokine inhibitor could be a potent source for TNF blockade in gene therapy trials as effective as anti-TNF antibodies which have been used for the treatment of rheumatoid arthritis. 17 Anti-TNF antibodies as well as TNF-R Ig fusion proteins have been used more efficiently at 10 times lower concentrations i.c. than systemically. 15 A single intracranial dose of 15 g TNF-R Ig protein at the onset of disease was sufficient to inhibit clinical signs but was not sufficient to block the relapse phase. The short half-life of these proteins, together with the impossibility of frequent intracranial injections, makes this approach technically difficult. In this regard, genetic delivery has, therefore, a clear long-term advantage; in addition, it is unlikely that we can achieve such high levels of protein concentration by gene delivery, which may result in systemic immunosuppression.
Our treatment was initiated at day 12 after immunization to target the effector stage of the disease. At this time the T cell response to spinal cord antigens has fully
Figure 4 Cloning of the human p55 TNF receptor linked to a murine Ig backbone sequence, into the retrovirus vector pBabeBleo human p55 (Hermes). The different stages of cloning strategy are shown. Principal restriction enzyme sites are indicated. huTNFR-ED: extracellular domain of TNF-receptor; hGH3′UTR: 3′ end of the untranslated region of human growth hormone; T.C.S.: thrombin cleavage site; mIgG1 (hinge + heavy chain, constant region):
Fc cluster of the mouse IgG1 backbone. 20, 23 developed and it is 1-2 days before significant cell accumulation in the CNS occurs. The clinical disease is associated with mononuclear cell infiltration but little or no demyelination. 27 There is a clear correlation between clinical signs and cell infiltration which is also accompanied by dysfunction of the blood-brain barrier. 28, 29 At day 24 after immunization, the clinical disease remits and the cellular infiltration is lost; 28 thus, histological analysis which was not informative was not performed.
In this study treatment with both LTR-driven IFN␤ and IFN␤-(NSE) of mice with CREAE reduced clinical severity of the disease. Likewise, long-term administration of IFN␤ protein was beneficial to the course of rat EAE; however, termination of treatment caused worsening of the disease. 13 The difference in the efficiency of these constructs is possibly due to selective expression of the NSE promoter expression by neuronal cells, compared with the nonselective expression of the LTR-driven IFN␤ which could be expressed in other cell types including CNS-resident glial cells. Despite the tissue specificity of the NSE promoter, the selective expression was not sufficient to reduce clinical scores to levels observed with the LTRdriven IFN␤. Although the in vivo data would support this view it was not possible to demonstrate the precise localization of expression by IFN␤-specific immunochemistry, probably due to low level of expression. This has been observed with most other plasmid cytokine DNA tested. 6 This study demonstrates that both IFN␤ and TNF antagonists are potential candidates for gene delivered therapy. It will be important to determine the effectiveness of this therapeutic approach in relapsing disease. It is possible that different cytokines or cytokine inhibitors will be effective at different stages of the pathogenic process.
Materials and methods

Bacterial strains
All the plasmid and retrovirus vectors used were grown in E. coli DH5␣ competent cells (supE44 DlacU169 f80
Figure 5 Western blot analysis of the human p55 TNF receptor/Ig chimeric protein in COS-7 cells. Supernatants and cells from the COS-7 transfected cells (10 6 cells) were used for the detection of the TNF receptor/Ig product. The arrow indicates the chimeric protein detected in the medium. Symbols M, S and C are as in Figure 2. Lane 1: mock-transfected; lane 2: Hermes transfectants.
lacZDM15 hsdR17 recA1 endAl gyrA96 thi-1 relA1) unless otherwise indicated.
Animals and disease induction
Biozzi ABH mice were bred at the Institute of Ophthalmology, London, UK, following Home Office and Institutional guidelines. Six to eight week-old mice were injected in the flank with 1 mg of mouse spinal cord homogenate (SCH) in incomplete Freund's adjuvant supplemented with 60 g mycobacterium, on day 0 and repeated on day 7, as described previously. 15 Animals were monitored up to day 24 after immunization and clinical signs of disease scored as follows: 0 = normal, 1 = flaccid tail, 2 = impaired righting reflex, 3 = partial paralysis and 4 = complete paralysis. 15 Clinical signs of a lower severity than typically observed were scored 0.5 lower than the grade indicated.
Vectors and cloning strategies IFN␤ expressing vectors: The sequence of the single copy murine IFN␤ gene described previously 24 was used to design PCR oligonucleotide primers to the 5′ (sequence 1) and 3′ end (sequence 2) of the coding region as below:
5′TGAAGACCTGTCAGTTGATGCCTCAGA 3′ DBA/1 mouse genomic DNA was purified from spleens 30 and a full-length coding sequence for IFN␤ was synthesized by PCR (40 cycles, 94°C for 1 min, 60°C for 1 min, 72°C for 3 min). After filling-in the ends with Klenow the 579 bp fragment (including the translation start and termination codons), was ligated into the SmaI site of the pUC18 plasmid vector. 31 Following transformation, positive colonies were selected on IPTG and X-gal plates. 32 The orientation of the inserts was determined by restriction analysis of plasmid DNA. A clone having the cDNA orientated 3′ to 5′ in the polylinker of pUC18 named K1 was sequenced by the dideoxy chain termination method. 33 Finally, the 608 bp EcoRI (filled-in with Klenow)-SalI fragment was subcloned into the SnaBI-SalI restriction sites of the retrovirus vector pBabeBleo 20 and this construct was named ApHRO (LTR-driven IFN␤).
The rat neuron-specific enolase NSE gene 5′ end including the promoter was excised from the pNSECAT plasmid vector 21 (kindly provided by Dr JG Sutcliffe, Scripps Clinic, La Jolla, CA, USA), as a 1800 bp HindIII (filled-in with Klenow)-SacI fragment and subcloned into SmaI-SacI restriction sites of pUC18. The resulting new clone was named 1␤. Subsequently, the mouse IFN␤ cDNA was excised from the K1 clone as an EcoRI-HindIII 608 bp fragment and subcloned into the BamHI (blunt/filled-in with Klenow)-HindIII restriction sites of 1␤ vector. This intermediate vector was named clone 6.
Clone 6 was supplemented with an SV40 polyadenylation signal from pGL2-Basic plasmid vector (Promega, Southampton, UK) as follows: the rat NSE promoter and the mouse IFN␤ gene were digested off as a 'cassette' of 2370 bp fragment with restriction sites: EcoRI (filled-in with Klenow)-SalI, and was cloned into the SmaI-XhoI restriction sites of pGL2-Basic plasmid vector. The resulting new construct, carrying the NSE-driven IFN␤ gene with the polyadenylation signal of SV40, was named NIKI.
Retrovirus vector expressing a TNF antagonist
The human bivalent p55 extracellular domain (ECD) TNF receptor linked to a mouse immunoglobulin IgG1 backbone 19 was excised from the pCMV4 vector 22 as a 2600 bp ClaI (filled-in with Klenow)-SalI fragment after having been grown in M147 dam-E. coli strain. 34 This 2600 bp fragment was subcloned into the SnaBI-SalI restriction site region of the retrovirus vector pBabeBleo. 20 The retrovirus construct obtained was named Hermes. A similar gene construct was also assembled with an irrelevant insert gene and used as an additional control for testing in TNF cytotoxicity assays (Figure 6b, GPenvAM12+) .
All DNA fragments used for subcloning were purified, following gel electrophoresis, by DEAE cellulose chromatography. 35 Preparation of purified DNA Bacteria, with the plasmid of interest, were grown in Luria-Bertani medium 30 overnight, at 37°C with 100 g/ml ampicillin (Sigma, Poole, UK). High purity DNA was prepared by Qiagen anion-exchange resin columns according to the suppliers protocol (Qiagen, Dorking, UK).
Cell cultures
AB/H Biozzi mouse immortalized fetal kidney fibroblast line (TSF) was generated following infection with a retrovirus vector carrying the neomycin resistance gene having a temperature-sensitive mutant SV40 large T antigen also containing a U19 mutation (pZipNeoSV40U19tsA58). 36 These ABH cells, the COS-7 cell line (Green Monkey kidney fibroblasts), 37 the human NB100 (neuroblastoma cells) 38 and the human amphotropic packaging cell line ␣-BOSC23, 39 were grown and maintained in Dulbecco's modified Eagle's medium (DMEM) containing 10% (v/v) fetal bovine serum (FBS), 2.5 U/ml penicillin, 2.5 g/ml streptomycin and 2 mm glutamine (GIBCO BRL Life Technologies, Paisley, UK). The mouse amphotropic GPenvAM12 packaging cells 40 were grown and maintained in the above medium, but with 10% new born calf serum (NBS).
Transfections and infections of cell lines
For the expression of the constructs described above (clone 6, ApHRO, NIKI and Hermes) in the transiently (COS-7, NB100, ␣-BOSC23) or permanently (GPenv-AM12) transfected cell lines, 20 g of vector DNA was used with the Ca 2+ -phosphate precipitation method as previously described. 41 Viral supernatants from the transiently transfected ␣-BOSC23 packaging cell line and permanently transfected GPenvAM12 cells were collected. The supernatants were frozen at −70°C until used for the infections as described below. Permanently transfected cells were selected and maintained in medium with 25 g/ml phleomycin (Sigma). Infection of ABH mouse TSF cell lines with the viral supernatants was carried out as follows. Initially, the sensitivity of ABH mouse fibroblasts to the selective drug phleomycin was assessed. It was determined that 25 g/ml of phleomycin was efficient to cause cell death within a 5 day period. 5 × 10 4 TSF cells were seeded per 9 cm diameter cell culture dish. Eighteen hours later, the supernatants with the retroviruses were added overnight to the cells in the presence of 0.8 g/ml polybrene (Sigma). This was repeated 2 days later. The plates were replenished with fresh medium, and after 48 h recovery, selection was initiated in the presence of 25 g/ml phleomycin and the culture was expanded.
In Hermes transfection studies, transfectants of an irrelevant insert were made in a similar retrovirus vector (control).
Western blot analysis Serum-free supernatants were collected after 48 h culture from the transfected 80-90% confluent cell cultures (COS-7 or NB100) and centrifuged at 1000 g for 5 min to discard cell debris and stored frozen at −70°C. Of these supernatants 4-5 ml were made to 0.5% SDS final concentration, and boiled for 5 min. Proteins were precipitated with 9 volumes of methanol overnight at −20°C. This solution was centrifuged at 4°C at 21 000 g for 30 min in a SS34 SORVALL rotor (Sorval Instruments, Delaware, USA) and the precipitated protein dissolved in 50 l SDS-PAGE loading buffer without ␤-mercaptoethanol. Before electrophoresis, samples were boiled for 5 min, cooled on ice and loaded on to a 12% SDS gel for PAGE. 42 Cells were collected by scraping, using a rubber policeman with PBS and centrifuged at 1000 g for 10 min. The cell pellet was resuspended in 0.5 ml PBS, transferred to an Eppendorf tube, pelleted and dissolved in 50 l of SDS-PAGE loading buffer and boiled for 5 min before loading on to a 12% SDS gel for PAGE.
Immunoblotting
Samples, separated by SDS-PAGE, were electroblotted on to nitrocellulose membranes (Schleicher & Schü ll, Dassel, Germany) and probed using a rabbit antiserum to mouse IFN␤ (Lee Biomolecular Research, San Diego, CA, USA) as a primary antibody in a 1:1000 dilution and sheep or donkey anti-rabbit Ig antibody conjugated with horseradish peroxidase (Amersham International, Bucks, UK) as a secondary detection antibody. For the detection of TNFR/Ig chimeric protein an anti-mouse Ig horseradish peroxidase-conjugated antibody in a 1:1000 dilution was used (Amersham). Western blots were developed by using the ECL system (Amersham) and exposed to Amersham 'Hyperfilm' for 1-5 min.
TNF cytotoxicity assay
In order to measure the protective effect of human p55 TNFR/Ig chimeric protein on TNF cytotoxic activity, WEHI 164 (clone 13) fibrosarcoma cells were used as previously described. 43 Antiviral activity IFN␤ was assayed by inhibition of the cytopathic effect of encephalomyocarditis virus (EMC) (kindly provided by Dr I Kerr, ICRF, London, UK) on murine LTK (−) fibroblasts as described previously. 44 Intracranial DNA injection Approximately 100 g of the plasmid DNA was dissolved in 30 l PBS and mixed with 3 g lipofectin reagent (GIBCO; 1 mg/ml). The plasmid-cationic liposome complex was allowed to stand at room temperature for 15 min. A single injection of the plasmid-cationic liposome complex, final volume 30 l, was administered i.c. within the right frontal lobe of mice anesthetized with Halothane (May and Baker, Dagenham, UK) shortly before the onset of disease, on day 12 after inoculation. Following injection, the 0.5 ml insulin syringe (27 gauge needle; Surgicon, Leeds, UK) was left in place for 20 s to prevent loss of complex and allow diffusion of DNA. Mice were chosen at random to form three groups expressing IFN␤ (n = 7), IFN␤-(NSE) (n = 10) and human p55 TNFR/Ig (n = 5) and two control groups with lipofectin in PBS only (n = 5), and a control group injected with PBS without any plasmid DNA or lipofectin treatment (n = 5).
Statistical analysis
The data are presented as the mean clinical score ± standard error and the mean day of onset ± s.e.m. Statistical analysis between groups was performed using MannWhitney U nonparametric ranking test.
